Eurofins CDMO
Planegg, DE · San Diego, CA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
81.6
Signal Score
✓ FDA Inspections (4)
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: Eurofins CDMO
- Signal Score
- 81.6/100 (as of 2026-04-29)
- Quality Compliance
- 100.0/100 — Bonus: 3 consecutive NAI inspections
- Headquarters
- Planegg, DE · San Diego, CA
- Modalities
- Biologics, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Eurofins CDMO
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Bonus: 3 consecutive NAI inspections
Source: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-12-12)
Bonus: 3 consecutive NAI inspections
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: Eurofins Scientific
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Eurofins Scientific
Financial assessment: 68.0/100
Capacity
63.0
2 manufacturing sites
Sites: Planegg, DE, San Diego, CA
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
Recent Press8 articles
2 manufacturing sites
Eurofins CDMO FDA Inspection History
2025-12
2025-06
2025-03
2024-07
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-12-12 | Philadelphia, Pennsylvania | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
| 2025-06-27 | Winston Salem, North Carolina | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
| 2025-03-26 | Irwindale, California | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
| 2024-07-19 | Centennial, Colorado | Human Cellular, Tissue, and Gene Therapies | No | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Jul 04, 2026
Recent News 8 articles
Dr. Kirithivasan Venkatesan Appointed as Senior Director – Process R&D at Eurofins CDMO India - hrtoday.in
Dr. Kirithivasan Venkatesan Appointed as Senior Director – Process R&D at Eurofins CDMO India hrtoday.in
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - BioSpace
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing BioSpace
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Business Wire
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing Business Wire
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Bluefield Daily Telegraph
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing Bluefield Daily Telegraph
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Yahoo Finance
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing Yahoo Finance
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - The Manila Times
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study The Manila Times
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ... - Caledonian Record
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ... Caledonian Record
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study Bitget
Frequently Asked Questions About Eurofins CDMO
How many FDA inspections does Eurofins CDMO have on record?
CDMO Signal tracks 4 FDA inspections for Eurofins CDMO, sourced from the FDA inspection database. See the full inspection history above.
Has Eurofins CDMO received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Eurofins CDMO.
What is Eurofins CDMO's CDMO Signal Score?
Eurofins CDMO has a Signal Score of 82/100, based on quality, operations, financial stability, and capacity data.
Evaluating Eurofins CDMO for a manufacturing program?
Use the free AI matchmaker to compare Eurofins CDMO against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Syngene International
Bengaluru, India
Signal Score: 79.7
Biologics, Cell Therapy
Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
Biologics, mAb, Cell Therapy, Gene Therapy (AAV), Oligonucleotide, mRNA, Small Molecule
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy